Research ArticleOriginal Article

Is adjuvant chemotherapy necessary for early gastric cancer?

Yu Mei, Tienan Feng, Min Yan, Zhenggang Zhu and Zhenglun Zhu
Cancer Biology & Medicine April 2022, 19 (4) 518-532; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0636

References

  1. 1.↵
    2. Bray F,
    3. Ferlay J,
    4. Soerjomataram I,
    5. Siegel RL,
    6. Torre LA,
    7. Jemal A.
    Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–24.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Machlowska J,
    3. Baj J,
    4. Sitarz M,
    5. Maciejewski R,
    6. Sitarz R.
    Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020; 21: 4012.
    OpenUrl
  3. 3.↵
    2. Johnston FM,
    3. Beckman M.
    Updates on management of gastric cancer. Curr Oncol Rep. 2019; 21: 67.
    OpenUrl
  4. 4.↵
    2. Sukri A,
    3. Hanafiah A,
    4. Mohamad Zin N,
    5. Kosai NR.
    Epidemiology and role of Helicobacter pylori virulence factors in gastric cancer carcinogenesis. APMIS. 2020; 128: 150–61.
    OpenUrl
  5. 5.↵
    2. Kumarasinghe MP,
    3. Bourke MJ,
    4. Brown I,
    5. Draganov PV,
    6. McLeod D,
    7. Streutker C, et al.
    Pathological assessment of endoscopic resections of the gastrointestinal tract: a comprehensive clinicopathologic review. Mod Pathol. 2020; 33: 986–1006.
    OpenUrl
  6. 6.↵
    2. Kim JW,
    3. Hwang I,
    4. Kim MJ,
    5. Jang SJ.
    Clinicopathological characteristics and predictive markers of early gastric cancer with recurrence. J Korean Med Sci. 2009; 24: 1158–64.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    2. Lai JF,
    3. Kim S,
    4. Kim K,
    5. Li C,
    6. Oh SJ,
    7. Hyung WJ, et al.
    Prediction of recurrence of early gastric cancer after curative resection. Ann Surg Oncol. 2009; 16: 1896–902.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    2. Saka M,
    3. Katai H,
    4. Fukagawa T,
    5. Nijjar R,
    6. Sano T.
    Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer. 2008; 11: 214–8.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Lai JF,
    3. Xu WN,
    4. Noh SH,
    5. Lu WQ.
    Effect of world health organization (who) histological classification on predicting lymph node metastasis and recurrence in early gastric cancer. Med Sci Monit. 2016; 22: 3147–53.
    OpenUrl
  10. 10.↵
    National, Comprehensive, Cancer, Network. National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2020, Gastric Cancer).
  11. 11.↵
    Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021; 24: 1–21.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Wang FH,
    3. Shen L,
    4. Li J,
    5. Zhou ZW,
    6. Liang H,
    7. Zhang XT, et al.
    The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019; 39: 10.
    OpenUrl
  13. 13.↵
    2. Paoletti X,
    3. Oba K,
    4. Burzykowski T,
    5. Michiels S,
    6. Ohashi Y,
    7. Pignon JP, et al.
    Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. J Am Med Assoc. 2010; 303: 1729–37.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    2. Sasako M,
    3. Sakuramoto S,
    4. Katai H,
    5. Kinoshita T,
    6. Furukawa H,
    7. Yamaguchi T, et al.
    Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011; 29: 4387–93.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    2. Noh SH,
    3. Park SR,
    4. Yang H-K,
    5. Chung HC,
    6. Chung I-J,
    7. Kim S-W, et al.
    Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (classic): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 1389–96.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14: 101–12.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    2. Amin MB,
    3. Edge SB,
    4. Greene FL,
    5. Brierley JD.
    AJCC cancer staging manual. 8th ed. New York: Springer; 2017.
  18. 18.↵
    2. Brierley JD,
    3. Gospodarwicz MK,
    4. Wittekind C,
    5. Amin MB.
    TNM classification of malignant tumours. 8th ed. Oxford: Wiley Black well; 2017.
  19. 19.↵
    2. Bartley AN,
    3. Washington MK,
    4. Colasacco C,
    5. Ventura CB,
    6. Ismaila N,
    7. Benson AB 3rd., et al.
    Her2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017; 35: 446–64.
    OpenUrlPubMed
  20. 20.↵
    2. Abdelfatah MM,
    3. Barakat M,
    4. Lee H,
    5. Kim JJ,
    6. Uedo N,
    7. Grimm I, et al.
    The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis. Gastrointest Endosc. 2018; 87: 338–47.
    OpenUrl
  21. 21.↵
    2. Li X,
    3. Liu S,
    4. Yan J,
    5. Peng L,
    6. Chen M,
    7. Yang J, et al.
    The characteristics, prognosis, and risk factors of lymph node metastasis in early gastric cancer. Gastroenterol Res Pract. 2018; 2018: 6945743.
  22. 22.↵
    2. Pereira MA,
    3. Ramos M,
    4. Dias AR,
    5. Faraj SF,
    6. Yagi OK,
    7. Safatle-Ribeiro AV, et al.
    Risk factors for lymph node metastasis in western early gastric cancer after optimal surgical treatment. J Gastrointest Surg. 2018; 22: 23–31.
    OpenUrl
  23. 23.↵
    2. Kim SM,
    3. Lee H,
    4. Min BH,
    5. Kim JJ,
    6. An JY,
    7. Choi MG, et al.
    A prediction model for lymph node metastasis in early-stage gastric cancer: toward tailored lymphadenectomy. J Surg Oncol. 2019; 120: 670–5.
    OpenUrl
  24. 24.↵
    2. Shin HB,
    3. An JY,
    4. Lee SH,
    5. Choi YY,
    6. Kim JW,
    7. Sohn SS, et al.
    Is adjuvant chemotherapy necessary in pT1N1 gastric cancer? BMC Cancer. 2017; 17: 287.
    OpenUrl
  25. 25.↵
    2. Kim SM,
    3. An JY,
    4. Lee J,
    5. Sohn TS,
    6. Kim S.
    Adjuvant chemotherapy versus chemoradiotherapy versus surgery alone for early gastric cancer with one or two lymph node metastasis. Ann Surg Oncol. 2018; 25: 1616–24.
    OpenUrl
  26. 26.↵
    2. Hester CA,
    3. Augustine MM,
    4. Mansour JC,
    5. Polanco PM,
    6. Yopp AC,
    7. Zeh HJ 3rd., et al.
    Adjuvant therapy is associated with improved survival in pT1N1 gastric cancer in a heterogeneous western patient population. Ann Surg Oncol. 2019; 26: 167–76.
    OpenUrl
  27. 27.↵
    2. Sakuramoto S,
    3. Sasako M,
    4. Yamaguchi T,
    5. Kinoshita T,
    6. Fujii M,
    7. Nashimoto A, et al.
    Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Eng J Med. 2007; 357: 1810–20.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    2. Bang Y-J,
    3. Kim Y-W,
    4. Yang H-K,
    5. Chung HC,
    6. Park Y-K,
    7. Lee KH, et al.
    Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (classic): a phase 3 open-label, randomised controlled trial. Lancet. 2012; 379: 315–21.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    2. Bang Y-J,
    3. Van Cutsem E,
    4. Feyereislova A,
    5. Chung HC,
    6. Shen L,
    7. Sawaki A, et al.
    Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687–97.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords